DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ciprofibrate
Ciprofibrate
Full Text
Joint Assessment Report Was Discussed by the Phvwp at Its Meeting in July 2007 and Finalised in September 2007
PI Changes for Fibrates
Fenofibrate, Bezafibrate, Ciprofibrate and Gemfibrozil Procedure Number
Methods of Chromatographic Determination of Medicines Decreasing the Level of Cholesterol
Update of Comparative Effectiveness of Lipid-Modifying Agents
Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
Estonian Statistics on Medicines 2013 1/44
Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs
Use of Cholesterol-Lowering Medications of Patients with Myocardial Infarction from 2007-2015 in Cardiology Clinic to “Mother Teresa” University Hospital in Albania
Review of Existing Classification Efforts
Study Protocol 1002-046 Amendment 1, 10 April 2017
Cholesterol-Interacting Layered Phyllosilicates for Suppressing Gastrointestinal Cholesterol Absorption
Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
FAMILIAL HYPERCHOLESTEROLAEMIA (Based on NICE Clinical Guideline 71, Last Updated Oct 2019)
Lipid Lowering: Another Method of Reducing Blood Pressure?
1. NAME of the MEDICINAL PRODUCT Fluvastatin 20 Mg / 40
The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS- 2 Cov-2 in Cell Culture Models
Top View
Ciprofibrate 100Mg Tablets
Antidiabetic Action of Bezafibrate in a Large Observational Database
ICCB-L Plate (10 Mm / 3.33 Mm) ICCB-L Well Vendor ID Chemical Name
(12) United States Patent (10) Patent No.: US 6,696,084 B2 Pace Et Al
A Review on Anti-Cholesterol Drugs and Their Mechanisms
Lipid Management in Patients with Endocrine Disorders: an Endocrine
2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
Prevention of Murine Atherosclerosis with Bempedoic Acid
Technology Road Mapping for Innovation Pathways of Fibrates: a Cross-Database Patent Review
Disease Agonists As Therapy for Autoimmune Α Peroxisome
PPAR-Mediated Toxicology and Applied Pharmacology
Accessibility Improving Information Using Online Patient Drug Reviews
New Product Highlights
Coadministration of Multidrug Therapy to Achieve Lipid Goals JAOA • Supplement 7 • Vol 104 • No 9 • September 2004 • S17 Drug Class Mechanism of Action
WO 2018/148417 Al 16 August 2018 (16.08.2018) W!P O PCT
Fenofibrate: a Novel Formulation (Triglide™) in the Treatment of Lipid Disorders: a Review
Proposed OPPTS Science Policy: PPAR-Alpha Mediated
ESC/EAS Guidelines for the Management of Dyslipidemias
Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark∗
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Trends in Lipid-Modifying Agent Use in 83 Countries
Treatment Guidelines for Dyslipidemia: Summary of the Expanded Second Version
PPARS - Peroxisome Proliferator Activated Receptor Activators and Fibrates Actions Sidney Carvalho Fernandes1, Anita L
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Transcriptional Regulation of Human Cytosolic Sulfotransferase 1C3 by Peroxisome Proliferator-Activated Receptor G in LS180 Human Colorectal Adenocarcinoma Cells
Lipid Modification to Reduce Cardiovascular Risk
(12) United States Patent (10) Patent No.: US 6,638,969 B1 Keller Et Al
Nilemdo, INN-Bempedoic Acid
L:\0900\0900PHARMAPPX .Wpd
Report on Investigation Results
Study Protocol 1002FDC-053 Amendment 1, 18 October 2017
1246 Cardiovascular Drugs
Emerging Antidyslipidemic Drugs